Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like he's still at work to me.
We need a squeeze,should be fun to watch him cover.
http://otcshortreport.com/CTIX.OB
Yo, Drano it's all about taking the shorts to the wood shed... time to squeeze the fuzzy's! go here: http://shortvolume.com/ put in ctix and change the time period,wait a sec... yep 100 share sells why?squeeze!!!!
OOOOOOOps Keltoi that was for our new boys..not you my friend!!
NICE BID!!!!
So true leifsmith. HIV-Cide results will not be ignored, that alone should put us all in the tropics. Time to show the WORLD our goods!!! GO NNVC!!!!
Here's daily volume:http://ih.advfn.com/p.php?pid=trades&symbol=NNVC
Hey, Doc-F write us up a piece. You can do it.
How to Submit a Letter to the Editor
Letters to the editor should only be sent to The Times, and not to other publications. We do not publish open letters or third-party letters.
Letters for publication should be no longer than 150 words, must refer to an article that has appeared within the last seven days, and must include the writer's address and phone numbers. No attachments, please.
We regret we cannot return or acknowledge unpublished letters. Writers of those letters selected for publication will be notified within a week. Letters may be shortened for space requirements.
Send a letter to the editor by e-mailing letters@nytimes.com or faxing (212) 556-3622.
You may also mail your letter to:
Letters to the Editor
The New York Times
620 Eighth Avenue
New York, NY 10018
About Letters
Thomas Feyer, the letters editor, gives tips for getting your letter published.
Additional Information?
Please call (212) 556-1831 for recorded instructions.
See: Op-Ed Submissions.
See: Opinion Video Submissions.
To write the editorial page editor, e-mail editorial@nytimes.com.
Other article submissions: Send your article to the editor of the department relevant to your piece (e.g. "News Editor," "Sports Editor") via regular mail to the address above.
Come on. Lets get real!Go to the Biotechs and pull their charts. Management has put us in a position to close the DEAL!!!!!! Here's an overlay for ya..check some more: http://finance.yahoo.com/echarts?s=NNVC.OB+Interactive#symbol=nnvc.ob;range=1y;compare=isco.ob;indicator=volume+stochasticslow;charttype=line;crosshair=on;ohlcvalues=0;logscale=off;source=; When the cycle is done we will fly!!!
Watch level 2:Seaside = Miller Tabak Roberts
But won't it be fun to watch your partners squirm? Allan's # 1 rule on the pennies has been VOLUME VOLUME VOLUME!!!!!!!!! hmmmm Who's right? I'LL STICK WITH ALLAN!
Allan posted his breakout chart this morning doc. Maybe some follow threw tomorrow.
Allan's still here.The Power of Biotechnology just today.
Can't speak for Coxs
NO!!!Right here:)"Well I can't call it like you do so I did a stragetic 'Lightening Up' today.".."Call me 'weak-hand' or whatever, I just don't want to see the 40's again unless I'm buying." I've got one more chunk to sell." THAT WAS YOU RIGHT? That was in the .70's right?
Right here:)"Well I can't call it like you do so I did a stragetic 'Lightening Up' today.".."Call me 'weak-hand' or whatever, I just don't want to see the 40's again unless I'm buying." I've got one more chunk to sell." SOOOOOO
The docs are doing this right!!! I have kids so i feel their pain. ARE WE THERE YET,ARE WE THERE YET...WE WILL GET THERE TRUST
That's right leifsmith..This is what the Docs are up against: http://www.bcg-usa.com/regulatory/docs/FDA_Presentations_Publications/SP6A06.pdf
Can you say capitulation? How many "longs" have done it again?
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan ...
en.wikipedia.org/wiki/Orphan_drug
No! Been there done that, good and cheap for the ground work. Now is the time to be in control. Remember there is still 22 months of cash in hand. When the submission is ready the price will take care of its self. Come on Docs get errrr done!!!!!
We have seen this time after time. Two spindles to support with volume. This was the best support I have watched here, time for news and an engulfing. Let them have it Docs or Cox
Looks like Kulnor has it nailed down.I have well over 100k and it comes down to trusting the Doc's. "I DO" thats why I'm in!!!
Not sure on price but do recall the pps dipping after. So it was a tough call back then. Maybe Cabel can help on that.
Well, I'm ok with it too. And I bought at the market back then and don't trade my position. It was offered to us all here in a minimum purchase of twenty-K. So DOCS lets get rocken and make us all happy!!!
Thanks seeker! Was going to ask the same. WTF?
I'm with ya noretreat. The convertions are being absorbed into a strong base. In a few weeks it could all come together with a bang. GOOOOOOOOOOOOOOOOOO NNVC!!!!!!!!!!!!!!!
Hang in there daBoze it's just the coffee pot dripping...sooooon it will be ready
Hey WILD, good to see ya still here. No crying here still have a full boat...tic.tic
Dr. Seymour said they are inspecting a facility for acquisition.
So you don't consider a lease an acquisition?
I'm with arch. Gaps closed support @ 1.37. BUY BUY BUY
Just in case you want some real answers:EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
Nanotechnology-based targeted anti-viral therapeutics
http://www.nanoviricides.com
eugene@nanoviricides.com
310-486-5677
Hint: may not aswer if your names DICK !
It's on his home page: NNVC Animal Study – 100% Survivability
This is a significant study. Details via link above. All the FluCide treated animals survived a 100% fatal protocol. Game-changing.
same link we have here from YAHOO
Well, from Allen today GAME-CHANGING!
Or this: The pre-IND meeting request filing will be important as well as various banks beginning to initiate coverage. A stock price increase with a subsequent move to the AMEX will also be important.
Here's some reality: 12 pages , 448 posts since 06/02/2010 03:04:40 PM and not even one positive post SO....OOOOH OK lottery short DAH!
OOPSY! There’s 3 new laws gaining attention in the NSS market reform arena: FINRA 4320 goes into effect on 2/28/11. It mandates 13 day buy-ins for open delivery failures FINALLY applying to shares of non-reporting corporations. FINRA 2010-043, also starting on 2/28/11 reinstates the “short sale exempt” (SSE) marking requirements for trade reporting and the OATS system. Those MMs accessing the bona fide MM exemption from executing pre-borrows or “locates” before admittedly naked short sales must now FORMALLY acknowledge the accessing of that universally-abused exemption. Being that these trades are theoretically being made to “inject liquidity” then the excuse to hide the related trade data from the public’s eyes goes out the window. You can’t have it both ways and claim the bona fide MM exemption and later claim that the related trade data needs to be kept secret because it might reveal a “proprietary trading strategy
Dr. F how about a sticky note? https://sites.google.com/site/nanoviricides/
Ya, just need weekly stoch to tighten and up we go. S&P 500 is very close. GO NNVC!!!!!!!!!!!!!!
Flu season picks up, widespread in 5 states...http://www.huffingtonpost.com/2011/01/02/cdc-flu-season-picks-up-w_n_803287.html
Thanks to Dr. S
From our GREAT DRS.
Dear sound.c
I'm in Atlanta at the meeting mentioned in the news release
Drs. Diwan, Barton and I have just spent 3 hours with Dr Harris and the head of all dengue for the US government. The reality of the vaccine is very far from the story you read!
Sanofi has said that it will be 2016 or 2017 before the vaccine Is ready for sale
Let's hope that it works but getting a drug approved should be a helluva lot easier and faster than a vaccine
You can post this if you wish
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677